SGX:H02

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Haw Par's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: H02 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.3%

H02

-1.1%

SG Pharmaceuticals

-0.09%

SG Market


1 Year Return

-28.2%

H02

22.1%

SG Pharmaceuticals

-21.9%

SG Market

Return vs Industry: H02 underperformed the SG Pharmaceuticals industry which returned 22.2% over the past year.

Return vs Market: H02 underperformed the SG Market which returned -21.8% over the past year.


Shareholder returns

H02IndustryMarket
7 Day0.3%-1.1%-0.09%
30 Day2.6%3.7%2.4%
90 Day0.5%-4.5%-2.0%
1 Year-25.9%-28.2%24.0%22.1%-17.6%-21.9%
3 Year-11.3%-22.2%-11.4%-21.4%-20.1%-29.8%
5 Year37.6%13.3%5.5%-12.0%-5.0%-22.3%

Price Volatility Vs. Market

How volatile is Haw Par's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Haw Par undervalued compared to its fair value and its price relative to the market?

13.09x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: H02 (SGD9.51) is trading above our estimate of fair value (SGD6.24)

Significantly Below Fair Value: H02 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: H02 is good value based on its PE Ratio (13.1x) compared to the XA Pharmaceuticals industry average (26.1x).

PE vs Market: H02's PE Ratio (13.1x) is in line with the SG market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate H02's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: H02 is good value based on its PB Ratio (0.8x) compared to the SG Pharmaceuticals industry average (1.6x).


Next Steps

Future Growth

How is Haw Par forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Haw Par has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Haw Par performed over the past 5 years?

4.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: H02 has high quality earnings.

Growing Profit Margin: H02's current net profit margins (88.6%) are higher than last year (74%).


Past Earnings Growth Analysis

Earnings Trend: H02's earnings have grown by 4% per year over the past 5 years.

Accelerating Growth: H02's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: H02 had negative earnings growth (-15.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.1%).


Return on Equity

High ROE: H02's Return on Equity (6.1%) is considered low.


Next Steps

Financial Health

How is Haw Par's financial position?


Financial Position Analysis

Short Term Liabilities: H02's short term assets (SGD634.6M) exceed its short term liabilities (SGD107.2M).

Long Term Liabilities: H02's short term assets (SGD634.6M) exceed its long term liabilities (SGD820.0K).


Debt to Equity History and Analysis

Debt Level: H02 is debt free.

Reducing Debt: H02 has no debt compared to 5 years ago when its debt to equity ratio was 2%.

Debt Coverage: H02 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: H02 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Haw Par current dividend yield, its reliability and sustainability?

3.15%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: H02's dividend (3.15%) is higher than the bottom 25% of dividend payers in the SG market (2.52%).

High Dividend: H02's dividend (3.15%) is low compared to the top 25% of dividend payers in the SG market (5.36%).


Stability and Growth of Payments

Stable Dividend: H02's dividend payments have been volatile in the past 10 years.

Growing Dividend: H02's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (41.3%), H02's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.4yrs

Average management tenure


CEO

Ee Lim Wee (59 yo)

17yrs

Tenure

S$2,469,000

Compensation

Mr. Ee Lim Wee serves as Deputy Chairman at UOL Group Limited. Mr. Wee has been the Chief Executive Officer and President of Haw Par Corporation Limited since April 1, 2003. Mr. Wee has been an Acting Pres ...


CEO Compensation Analysis

Compensation vs Market: Ee Lim's total compensation ($USD1.82M) is about average for companies of similar size in the SG market ($USD1.67M).

Compensation vs Earnings: Ee Lim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ee Lim Wee
CEO, President & Executive Non-Independent Director17yrsS$2.47m0.20%
SGD 4.2m
Say Suan Chow
Group Financial Controllerno datano datano data
Kay Swee Lee
Legal Counsel & Company Secretary1.58yrsno datano data
Tang Lee
Manager of Corporate Communicationsno datano datano data
Edwin Chia
Human Resource Director3.75yrsno datano data
Meng Kwek
Regional General Manager of Underwater World Singapore Pte Ltd & Haw Par Leisure Pte Ltd18.75yrsno datano data

10.4yrs

Average Tenure

Experienced Management: H02's management team is seasoned and experienced (10.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ee Lim Wee
CEO, President & Executive Non-Independent Director17yrsS$2.47m0.20%
SGD 4.2m
Hiang Meng Gn
Non-Executive Independent Director6.17yrsS$55.00kno data
Cho-Yaw Wee
Non-Executive & Non-Independent Chairman42.75yrsS$100.00k0.55%
SGD 11.6m
Soo Jin Hwang
Non-Executive & Independent Director34yrsS$50.00kno data
Suan Lee
Non-Executive Independent Director24.83yrsS$50.00kno data
Ee-chao Wee
Non-Executive Deputy Chairman4.67yrsS$59.00k0.0063%
SGD 131.5k
Swee Yam Sim
Non-Executive Independent Director9.42yrsS$60.00kno data
Sat Pal Khattar
Non-Executive Independent Director43.75yrsS$65.00k0.043%
SGD 915.0k
Weng Keong Low
Non-Executive & Independent Director0.33yrno datano data
Kia Ngee Chew
Non-Executive Independent Director9.42yrsS$65.00kno data
Choon Chew
Non-Executive & Independent Director1.67yrsS$43.00kno data

9.4yrs

Average Tenure

71yo

Average Age

Experienced Board: H02's board of directors are considered experienced (9.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Haw Par Corporation Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Haw Par Corporation Limited
  • Ticker: H02
  • Exchange: SGX
  • Founded: 1969
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: S$2.103b
  • Shares outstanding: 221.19m
  • Website: https://www.hawpar.com

Number of Employees


Location

  • Haw Par Corporation Limited
  • No. 03-03 Haw Par Technocentre
  • 401 Commonwealth Drive
  • Singapore
  • 149598
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HAWP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
H02SGX (Singapore Exchange)YesOrdinary SharesSGSGDJan 1992
HAWP.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDOct 2011

Biography

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 12:38
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.